title: The fourth modality: immunotherapy for head and neck cancer hits pay dirt.
authors.affiliation: Director, Providence Oral, Head and Neck Cancer Program and Clinic, Providence Portland Medical Center, Portland, OR; Investigator, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR; Consultant, Head and Neck Institute, Portland, OR.
authors.forename: R Bryan
authors.initials: RB
authors.lastname: Bell
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018450:Disease Progression; D020869:Gene Expression Profiling; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008495:Medical Oncology / Q000639:trends*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines